Bicara therapeutics inc. common stock BCAX.US Overview
BetaUS StockHealthcare
(No presentation for BCAX)
BCAX AI Analysis & Strategy
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
BCAX Current Performance
-1.85%
Bicara therapeutics inc. common stock
0.98%
Avg of Sector
0.83%
S&P500
BCAX Key Information
BCAX Financial Forecast
Unit : USD
BCAX Earnings Table
No related data records
BCAX Profile
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.